Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Liabilities (2016 - 2023)

Historic Total Liabilities for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $12.4 million.

  • Aptevo Therapeutics' Total Liabilities fell 2210.51% to $12.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $12.4 million, marking a year-over-year decrease of 2210.51%. This contributed to the annual value of $16.2 million for FY2022, which is 7067.62% down from last year.
  • Per Aptevo Therapeutics' latest filing, its Total Liabilities stood at $12.4 million for Q3 2023, which was down 2210.51% from $12.7 million recorded in Q2 2023.
  • In the past 5 years, Aptevo Therapeutics' Total Liabilities ranged from a high of $58.2 million in Q1 2021 and a low of $9.9 million during Q2 2020
  • In the last 5 years, Aptevo Therapeutics' Total Liabilities had a median value of $37.0 million in 2020 and averaged $32.6 million.
  • Per our database at Business Quant, Aptevo Therapeutics' Total Liabilities skyrocketed by 48416.68% in 2021 and then tumbled by 7706.39% in 2023.
  • Aptevo Therapeutics' Total Liabilities (Quarter) stood at $41.6 million in 2019, then dropped by 11.1% to $37.0 million in 2020, then skyrocketed by 49.88% to $55.4 million in 2021, then crashed by 70.68% to $16.2 million in 2022, then fell by 23.58% to $12.4 million in 2023.
  • Its Total Liabilities stands at $12.4 million for Q3 2023, versus $12.7 million for Q2 2023 and $11.7 million for Q1 2023.